Truvada

(redirected from emtricitabine and tenofovir disoproxil fumarate)
Also found in: Dictionary.

Truvada

(tro͞o-vä′də)
A trademark for a drug consisting of a combination of emtricitabine and a prodrug of tenofovir.
References in periodicals archive ?
Emtricitabine and tenofovir disoproxil fumarate tablets are the genetic version of Gilead Sciences Inc.'s Truvada tablets.
28 October 2011 - US biopharmaceutical company Gilead Sciences Inc (NASDAQ:GILD) said that it has filed a new drug application (NDA) with the US Food and Drug Administration (FDA) for marketing approval of the Quad, a complete single-tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
15 August 2011 - US biopharmaceutical company Gilead Sciences Inc (NASDAQ:GILD) said today that a Phase III clinical trial (Study 102) of its fixed-dose, single-tablet Quad regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, being evaluated for HIV-1 infection in treatment-naive patients, has met its primary objective, which was non-inferiority at week 48 as compared to Atripla.
28 April 2010 - US biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) said yesterday it has obtained data supporting bioequivalence of a formulation of the fixed-dose combination of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride, 25 mg).